Over 300 Minnesota Auctions End Tomorrow 11/30 - Bid Now
Over 100 Total Lots Up For Auction at One Location - CA 12/02
Visit DOTmed at RSNA in Chicago. Booth 6801

Bodyport receives FDA clearance for the Bodyport Cardiac Scale

Press releases may be edited for formatting or style | August 09, 2022 Business Affairs

"The Bodyport Cardiac Scale is a significant step forward in the standard of care for the remote management of patients with cardiorenal conditions. By providing a longitudinal view of fluid status, care teams can more effectively manage their patients through simple, optimized lifestyle and medication adjustments," said Corey Centen, Co-Founder, President, and CTO, Bodyport.

Over 10 leading hospitals and healthcare systems across the U.S. have already participated in Bodyport's clinical studies. The company plans to roll out the technology more broadly later this year.

About Bodyport
Based in San Francisco, Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by collecting clinically actionable biomarkers from simple, daily experiences. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient's daily life. Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital.

Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Initialized Capital, Playground Global, Rock Health, and Y Combinator.

Back to HCB News

You Must Be Logged In To Post A Comment